Patient Demographics: G.G and H.T are both 16 year old Caucasian females. Clinical Presentation: G.G and H.T were both referred for investigation of primary amenorrhea. Neither girl had a particular phenotype, the onset of thelarche was age appropriate, at the age of 12 years. At presentation both had completed puberty with breast Tanner stage V, pubic hair stage V, both had an absence of menses. Relevant Past History: G.G has a background of Type 1 DM, diagnosed 1 year to presentation with excellent control. H.T had presented to her general practitioner 2 years prior with PCOS like symptoms, and was commenced on the contraceptive pill. Neither of the girls has a family history of late puberty. Evaluation: G.G had an age appropriate hormonal level and went on to have a pelvic U/S and subsequent MRI, with a finding of uterine didelphys with two separate endometrial cavities, two cervical canals, both distended due to haematocolpos, associated unilateral kidney hypoplasia. H.T had age appropriate hormonal levels, underwent a pelvic U/S and MRI, and was found to have an absent uterus and a rudimentary cervix, with no introitus that could be visualised, but had normal ovaries.
Interventions: G.G underwent a Vaginoplasty that required a two doyle nasal septal splints + silicon layers to be sewn in place to form a vaginal splint, with follow up dilation therapy. H.T requires ongoing dilation therapy and ongoing psychological support to understand and come to terms with the diagnosis. Discussion/Recommendations: Primary amenorrhea should be investigated in any girl with secondary sexual characteristics who has not had menstruation by the age of 15 years or 5 years post breast development. Primary amenorrhea is usually a result of genetic or anatomical abnormalities and in some cases if left undiagnosed can lead to a life threatening event. Secondary diagnoses such as Type 1 DM and PCOS can delay a diagnosis due to higher rates of secondary amenorrhea within these subgroups; these cases hope to highlight the need for thorough investigation in all girls with a presentation of amenorrhea. Background: Classic congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency (21-OHD) is characterized by cortisol and aldosterone deficiency and androgen excess and is divided into 2 subtypes: classic and nonclassic (NC). Depending on the degree of aldosterone deficiency, classic CAH is further subdivided into saltwasting (SW) and simple-virilizing (SV). There is some overlap in the clinical management of the classic (severe) and NC (mild) forms, although lifetime glucocorticoid therapy is not indicated for NC males. Patient Demographics: 8 y/o Caucasian male presented to our clinic for evaluation of possible CAH. Clinical Presentation: Patient presented with pubic hair and 3 year bone age advancement. Relevant Past History: Newborn screening for CAH was negative and patient had normal developmental milestones with no prior illnesses, surgeries, or hospitalizations. At age 8, he was noted to have public hair and advanced bone age. Physical examination was significant for testicular volume (4 cm 3 right, 5 cm 3 left) indicating onset of central puberty.
Relevant Family History: 13y/o sister was diagnosed with classic 21-OHD CAH following a positive newborn screen. She had mild clitoromegaly and no other genital ambiguity. She was treated with hydrocortisone and fludrocortisone from 2 weeks of age. CYP21A2 genotyping revealed mother heterozygous Q318X; father V281 L/I172N; patient V281 L/Q318x; sister I172N/Q318X. Evaluation: Early morning laboratory evaluation showed 17-hydroxyprogesterone (17-OHP) 368 ng/dL, androstenedione 59 ng/dL (31-65), plasma renin activity 1.7 ng/mL/h (0.8-2.0). ACTH stimulation test confirmed the diagnosis of NC CAH with 17-OHP 3395 ng/dL at 60 min. Interventions: Hydrocortisone 5 mg/2.5 mg/5 mg (9.5 mg/m 2 /day) and GnRH analogue were started. Nursing intervention included education to family about the various forms of CAH and emphasis on oral stress dosing and injectable hydrocortisone training to prevent adrenal crisis. Discussion/Recommendations: Our patient's phenotype and genotype were consistent with the diagnosis of NC CAH due to 21-OHD, despite his sister having classic CAH. Family genetic counseling was suggested. Treatment of classic and NC CAH includes prevention of short stature, prevention of adrenal insufficiency and management of early central puberty. Nurses should be aware of the genetic complexities of this endocrine condition and the possible wide range of phenotype and genotype within single families. Background: The rate at which new cases of Type 1 diabetes (T1D) in youth b 20 years old is increasing in the U.S. is a mounting pediatric public health concern; and age, race and ethnicity have significant impacts. Specific social determinants of health and sociodemographic (SD) characteristics -racial/ethnic minority, low SES, single parent home and underinsured-have consistently been associated with poorer glycemic control (GC) and self-management (SM) in adolescents with T1D. Purpose: The purpose of this systematic review was to evaluate sample demographics, and culturally responsive recruitment and reporting methods used in psychosocial and behavioral interventions focused on improving SM and GC in adolescents with T1D, to identify if studies were targeting these high risk groups and if current methods were being tailored to reach them. Description of Topic: Using a social determinants of health and health equity theoretical perspective, this review applied a culturally responsive research (CRR) framework to evaluate relevant interventions. Intervention studies, from 2006 to 2016, focused on adolescents (13-18yo) with T1D and improving SM and GC by psychosocial or behavioral methods, obtained from PsychInfo, PubMed and CINAHL, were evaluated using a CRR rubric. Twenty-eight studies met inclusion criteria; 14 reported on fewer than 3 of 7 SD categories. Of those that reported, overall study samples used convenience sampling methods, focused predominantly on white, middlehigh income, moderately GC'd adolescents from two-parent households with private insurance. Majority of studies scored poorly in cultural responsiveness in reporting analysis and interpretation, and moderately in culturally responsive reporting of SD descriptions of participants. Overall, studies lacked detailed recruitment and sampling methods, as relates to cultural inclusivity, neglecting to apply deliberate recruitment efforts and use of culturally responsive assessments for difficult to reach high risk groups. Clinical Implications: Pediatric endocrinology nurse interventionists must increase targeted efforts towards recruiting and sampling more high risk groups, by devising successful, culturally responsive methods of recruitment and sampling through community based participatory research, and including expanded SD reporting. These efforts will engage high risk participants and improve existing and novel interventions by making them relevant to the unique needs, goals and priorities of highest risk SD groups within pediatric endocrinology. Background: The social and physical contexts which make up the social determinants of health (SDOH) have tremendous impacts on youth development, health and well-being, especially for youth with chronic conditions. Many youth and families affected by SDOH also experience significant overlap of multiple health related social problems, and the stress of these SDOH can exacerbate existing chronic conditions, or spur new conditions. Despite knowledge and evidence of the impact of SDOH on pediatric health, clinicians rarely screen for, or address, SDOH in pediatric clinical settings and few SDOH screening tools are known for use in pediatrics. Purpose: To gain a better understanding of the scope of pediatric SDOH screening tools, an integrative review of the literature was conducted. Its purpose was to identify available SDOH screening tools used in pediatric settings, and evaluate their comprehensiveness and validity in assessing multiple SDOH. Description of Topic: A systematic search of 3 online databases yielded 499 articles. Thirteen articles relevant to the assessment of SDOH were evaluated and appraised using the five domain SDOH framework outlined by Healthy People 2020. Majority of studies were limited in the number of SDOH domains screened and the depth of screening. Tools were heterogeneous in methods used to assess SDOH risks and few were validated. Limited number of studies included youth or families in the initial development of tools. Clinical Implications: Despite growing recognition across healthcare communities that SDOH greatly influence pediatric chronic disease health risks, management and outcomes, there is a dearth of available high quality, multidimensional, comprehensive screening tools for pediatric nurses and care professionals. This review emphasizes the need for continued development of comprehensive and effective tools for assessing pediatric SDOH risk factors. Without assessing the multiple layers of risks, care plans may be practically and materially infeasible for families to follow, despite a family's willingness. Pediatric endocrine nursing care includes the assessment of the youth and family context in order to effectively evaluate resource needs. Therefore, pediatric endocrine nurses are well poised to address this knowledge and resource gap to improve the lives of the youth and families they serve. Background: Through collaboration within the Canadian Pediatric Endocrine Nurses (CPEN) network it has become evident that there are differences in practices in the use of injectable testosterone for hypogonadal and transgender males. Some clinics in Canada offer Testosterone injections subcutaneously following a pilot study conducted at McGill University Health Center in 2006 reporting its safe use and efficacy. Purpose: CPEN Nurses across 15 clinical centers in Canada have explored current prescribing, monitoring and teaching practices for injectable testosterone through an online survey. Results of this survey, patient reports and a review of the current literature will inform future best practice as it relates to injectable testosterone in youth. Description of Topic: Intramuscular testosterone injections have been used since the 1940′s. A change to subcutaneous administration was first described in 2006 due to the inconvenience and discomfort of monthly intramuscular dosing. Currently recommended dosing of Depot Testosterone
